Movement Alert｜INSILICO Rises 5.07% in Regular Trading, Phase III First Dosing Milestone and Chairman Share Purchase Boost Sentiment

Market Focus

Sep 17

On September 17, INSILICO rose 5.07% in regular trading, trading at HK$53.0 per share, with turnover of HK$159 million.

The rally was driven by a dual catalyst. The company's core AI-driven candidate Rentosertib completed first patient dosing in its Phase III clinical trial GENESIS-IPF-3 at Peking Union Medical College Hospital on September 10. The 52-week study plans to enroll 320 idiopathic pulmonary fibrosis patients and marks a global milestone as the first generative AI-discovered drug to enter Phase III. Rentosertib is a potentially first-in-class TNIK-targeting small molecule inhibitor discovered via the company's proprietary Pharma.AI platform.

Additionally, Chairman and CEO Aleksandrs Zavoronkovs purchased 113,500 shares on the open market between September 4 and 7 using personal funds, raising his stake to approximately 8.02% of outstanding shares, as part of a broader plan to invest up to HK$16 million. Citi maintained a Buy rating with a target price of HK$85, designating the stock as its top pick in the AI drug discovery subsector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/news/1161401032"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161401032\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161401032?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161401032","market":"us","top_or_hot":-1,"title":"Movement Alert｜INSILICO Rises 5.07% in Regular Trading, Phase III First Dosing Milestone and Chairman Share Purchase Boost Sentiment","media":"Market Focus","content":"<p><p>On September 17, INSILICO rose 5.07% in regular trading, trading at HK$53.0 per share, with turnover of HK$159 million.</p><p>The rally was driven by a dual catalyst. The company's core AI-driven candidate Rentosertib completed first patient dosing in its Phase III clinical trial GENESIS-IPF-3 at Peking Union Medical College Hospital on September 10. The 52-week study plans to enroll 320 idiopathic pulmonary fibrosis patients and marks a global milestone as the first generative AI-discovered drug to enter Phase III. Rentosertib is a potentially first-in-class TNIK-targeting small molecule inhibitor discovered via the company's proprietary Pharma.AI platform.</p><p>Additionally, Chairman and CEO Aleksandrs Zavoronkovs purchased 113,500 shares on the open market between September 4 and 7 using personal funds, raising his stake to approximately 8.02% of outstanding shares, as part of a broader plan to invest up to HK$16 million. Citi maintained a Buy rating with a target price of HK$85, designating the stock as its top pick in the AI drug discovery subsector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INSILICO Rises 5.07% in Regular Trading, Phase III First Dosing Milestone and Chairman Share Purchase Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INSILICO Rises 5.07% in Regular Trading, Phase III First Dosing Milestone and Chairman Share Purchase Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, INSILICO rose 5.07% in regular trading, trading at HK$53.0 per share, with turnover of HK$159 million.</p><p>The rally was driven by a dual catalyst. The company's core AI-driven candidate Rentosertib completed first patient dosing in its Phase III clinical trial GENESIS-IPF-3 at Peking Union Medical College Hospital on September 10. The 52-week study plans to enroll 320 idiopathic pulmonary fibrosis patients and marks a global milestone as the first generative AI-discovered drug to enter Phase III. Rentosertib is a potentially first-in-class TNIK-targeting small molecule inhibitor discovered via the company's proprietary Pharma.AI platform.</p><p>Additionally, Chairman and CEO Aleksandrs Zavoronkovs purchased 113,500 shares on the open market between September 4 and 7 using personal funds, raising his stake to approximately 8.02% of outstanding shares, as part of a broader plan to invest up to HK$16 million. Citi maintained a Buy rating with a target price of HK$85, designating the stock as its top pick in the AI drug discovery subsector.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1161401032","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161401032","pubTimestamp":1789610020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, INSILICO rose 5.07% in regular trading, trading at HK$53.0 per share, with turnover of HK$159 million.The rally was driven by a dual catalyst. The company's core AI-driven candidate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"走势警报|INSILICO 常规交易上涨 5.07%，III 期首次给药里程碑和董事长购买股票提振情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On September 17, INSILICO rose 5.07% in regular trading, trading at HK$53.0 per share, with turnover of HK$159 million.The rally was driven by a dual catalyst. The company's core AI-driven candidate Rentosertib completed first patient dosing in its Phase III clinical trial GENESIS-IPF-3 at Peking Union Medical College Hospital on September 10. The 52-week study plans to enroll 320 idiopathic pulmonary fibrosis patients and marks a global milestone as the first generative AI-discovered drug to enter Phase III. Rentosertib is a potentially first-in-class TNIK-targeting small molecule inhibitor discovered via the company's proprietary Pharma.AI platform.Additionally, Chairman and CEO Aleksandrs Zavoronkovs purchased 113,500 shares on the open market between September 4 and 7 using personal funds, raising his stake to approximately 8.02% of outstanding shares, as part of a broader plan to invest up to HK$16 million. Citi maintained a Buy rating with a target price of HK$85, designating the stock as its top pick in the AI drug discovery subsector.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}